Volume | 560,492 |
|
|||||
News | - | ||||||
Day High | 1.595 | Low High |
|||||
Day Low | 1.525 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Atossa Therapeutics Inc | ATOS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.58 | 1.525 | 1.595 | 1.52 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,913 | 560,492 | $ 1.56 | $ 873,413 | - | 0.5901 - 2.31 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:39:22 | 100 | $ 1.55 | USD |
Atossa Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
194.22M | 125.30M | - | 0 | -30.09M | -0.24 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Atossa Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATOS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.43 | 1.595 | 1.32 | 1.46 | 1,321,106 | 0.12 | 8.39% |
1 Month | 1.84 | 2.31 | 1.24 | 1.75 | 2,737,853 | -0.29 | -15.76% |
3 Months | 0.835 | 2.31 | 0.8279 | 1.59 | 1,772,401 | 0.715 | 85.63% |
6 Months | 0.6557 | 2.31 | 0.62 | 1.44 | 1,026,633 | 0.8943 | 136.39% |
1 Year | 0.6202 | 2.31 | 0.5901 | 1.26 | 852,263 | 0.9298 | 149.92% |
3 Years | 1.77 | 9.80 | 0.50 | 3.76 | 3,324,485 | -0.22 | -12.43% |
5 Years | 3.08 | 9.80 | 0.50 | 3.18 | 3,495,863 | -1.53 | -49.68% |
Atossa Therapeutics Description
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |